TrialJournal of hematology & oncology2026

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Ignacio Melero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.